Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing
![Vivalytic](https://www.randox.com/wp-content/uploads/2019/11/BiSci-Square-Blog-Image-SEP18.jpg)
15 November 2019
Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing
Vivalytic will revolutionise the way laboratories and healthcare professionals access molecular diagnostics. A result of a collaboration between Bosch – providing innovative strength – and Randox Laboratories – dedicated to improving global healthcare – Vivalytic is the new innovative testing platform. It’s the perfect fit for any laboratory, with numerous benefits to enhance testing capabilities.
The Vivalytic is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. Vivalytic cartridges are compact, utilising micro-fluidics to enable simple and accurate diagnostic testing. Hi-Plex tests utilise Randox patented Biochip Technology, enabling end-point qualitative PCR and providing multiple test results from each sample. Lo-Plex tests are based on a variety of detection methods including real-time qualitative PCR and melting curve analysis. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required.
Vivalytic is the perfect fit for a healthcare professional in a point of care setting to a laboratory, which can implement the Vivalytic Up – modular and expandable testing system for higher throughput.
Benefits include:
- Fully Automated Platform
- Protected System
- Direct and Clear Results
- Hygienic and Space Saving
Vivalytic Test Menu
Vivalytic offers the most comprehensive multiplex screening test for infectious diseases including respiratory, genitourinary and hospital acquired infections; simultaneously detecting both viral and bacterial infections (please see figure 1.).
Respiratory Tract Infection Array | Sexually Transmitted Infection Array | Hospital Acquired Infections | |
Bacterial | Viral | ||
Bordetella Pertussis | Influenza A | Chlamydia trachomatis (CT) | Methicillin-resistant
Staphylococcus aureus (MRSA) |
Chlamydophila pneumoniae | Influenza B | Ureaplasma urealyticum (UU) | Methicillin-sensitive
Staphylococcus aureus (MSSA) |
Haemophilus influenzae | Human adenovirus A/B/C/D/E | Neisseria gonorrhoea (NG) | Methicillin-resistant
coagulase-negative Staphylococci (MRCoNS) |
Legionella pneumophila | Human bocavirus 1/2/3 | Mycoplasma genitalium (MG) | |
Moraxella catarrhalis | Human coronavirus 229E/NL63 | Trichomonas vaginalis (TV) | |
Mycoplasma pneumoniae | Human coronavirus OC43/HKU1 | Haemophilus ducreyi (HD) | |
Streptococcus pneumoniae | Human enterovirus A/B/C | Mycoplasma hominis (MH) | |
Bordetella parapertussis | Human Metapneumovirus | Treponema pallidum (TP) | |
Human parainfluenza virus 1 | Herpes simplex Virus 1 (HSV-1) | ||
Human parainfluenza virus 2 | Herpes simplex Virus 2 (HSV-2) | ||
Human parainfluenza virus 3 | |||
Human parainfluenza virus 4 | |||
Human respiratory syncytial virus A & B | |||
Human rhinovirus A/B/C |
Figure 1.
Lower and Upper Respiratory Tract Infections
The economic burden of respiratory illness in the UK costs a staggering £11 billion every year on lung disease alone1. Lower respiratory tract infections (LRIs) are a substantial public health problem and a leading cause of illness and death in people of all ages2. It is estimated that LRI causes nearly 4 million deaths annually3. Upper respiratory tract infections (URIs) account for an estimated 10 million outpatient appointments a year. Most of these appointments end with physicians needless writing of antibiotic prescriptions4.
Randox Biosciences offers a Respiratory Multiplex Array which rapidly detects and identifies the cause of 22 bacterial and viral pathogens helping to reduce the risk of antibiotic resistance. Given that only bacterial infections can be treated with antibiotics, rapid diagnostic tests are urgently needed to distinguish between bacterial and viral infections. This test will aid clinicians in their selection of the most appropriate antibiotic treatment for patients. GPs would have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily writing prescriptions.
The test is performed utilising our Biochip Technology which enables the simultaneous detection of multiple results from one patient sample. Biochip Technology powers Vivalytic which is the all-one solution for molecular diagnostics.
The main benefits of the Respiratory Multiplex Array are:
- Turnaround time of 2 hours
- Validated for sputum, lavage and nasopharyngeal samples
- Panel includes viral and bacterial species to consolidate testing
Randox Biosciences are committed to the ongoing development of diagnostic tests, through our research into numerous disease areas, to improve health worldwide.
MEDICA World Forum for Medicine International Trade Fair
Randox Biosciences team will be attending Medica from the 18th – 21st of November 2019 at Messe Dusseldorf, Germany. Stop by and say hello to some of our team members at our stand, and to learn more about our latest game-changing partnership with Bosch – the innovative Vivalytic platform!
Medica is at the forefront of new approaches in laboratory medicine, addressing the complexity of an evolving healthcare landscape. This event attracts more than 5,100 exhibitors from 70 countries, engaging diverse professionals enabling them to discover new and innovative solutions to improving patient outcomes through effective lab testing, diagnosis and treatment.
To learn more about the Vivalytic offering, visit https://www.randoxbiosciences.com/clinical-laboratory/infectious-diseases/molecular-arrays/ or email us at info@randoxbiosciences.com
References:
- British Lung Foundation. (2019). Estimating the economic burden of respiratory illness in the UK. [online] Available at https://www.blf.org.uk/policy/economic-burden [Accessed 06 Nov. 2019].
- The Lancet Infectious Diseases. (2015). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. [online] Available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30396-1/fulltext [Accessed 29 Oct. 2019].
- Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.
- Thomas, M. and Bomar, P. The National Centre for Biotechnology. Upper Respiratory Tract Infection. United States of America.